April 2, 2014, Waltham, MA - Polaris Partners today announced that Kevin Bitterman, PhD has been promoted to Partner of the firm.  Kevin joined Polaris in 2004 and focuses on healthcare investing.  A co-founder of Sirtris Pharmaceuticals (sold to Glaxo Smith Kline in 2008) and Genocea Biosciences (NASDAQ: GNCA), Kevin has been intimately involved in the creation of a number of Polaris-backed companies including the 2013 formation of Editas Medicine, where he currently serves as Interim CEO.


"For nearly a decade, Kevin has delivered incredible value to our partnership and our companies," said Amir Nashat, Polaris Managing Partner.  "His passion for science, entrepreneurial spirit, and pragmatic approach to company building has proven to be a tremendous asset for our portfolio.  We are thrilled to recognize his commitment with this promotion and we look forward to his continued contributions now as a Partner in the firm."


In addition to his interim role at Editas, Kevin currently represents Polaris on the boards of InSeal Medical, Genocea Biosciences (NASDAQ: GNCA), Kala Pharmaceuticals, Neuronetics, Inc., Visterra, Inc., Taris Biomedical, and Vets First Choice.


"Our collaboration with Kevin has been rooted in mutual respect and a shared passion for creating life-changing medicines," said Chip Clark, Chief Executive Officer of Genocea Biosciences.  "He has served as an outstanding partner to our company and we congratulate him on this well-deserved promotion."


Prior to joining Polaris, Kevin completed his PhD in genetics at Harvard Medical School.  His doctoral research focused on the molecular regulation of caloric restriction and on modulation of a novel class of protein deacetylases.  He earned a Bachelor of Science degree, graduating with highest honors, from Rutgers University.


"Kevin's elevation to Partner is a testament to his long term commitment and ongoing success, but it also reflects the positive energy and momentum at our firm," said Terry McGuire, Co-Founder of Polaris.  "As a Founding Partner, my ultimate goal is to successfully mentor the next generation of venture investors so that our legacy of thoughtful investing continues well into the future.  We are extremely proud of all that Kevin has accomplished at Polaris and know that the best is yet to come."


About Polaris Partners


Founded in 1996, Polaris Partners has more than $3.5 billion in capital under management invested into a diverse portfolio of technology and healthcare companies throughout their lifecycles.  From the earliest startup phases through the growth stages, Polaris Partners takes minority and majority positions alongside outstanding management teams to help grow industry leading companies.  With offices in Boston, San Francisco and Dublin, Polaris partners with an unparalleled network of repeat CEOs, entrepreneurs, top scientists and emerging innovators who are positioned to make a significant impact in their fields and vastly improve the way in which we all live and work.  The result:  Hundreds of growing companies, thousands of jobs generated, and billions of dollars of value created.  For more information, visit: www.polarispartners.com.


Contact:  Emily Mendell, Polaris Partners, em@polarispartners.com, 781-522-6732




Polaris Partners